What are the contraindications of using an evening‑primrose‑oil vaginal suppository for cervical ripening in a pregnant woman with a history of hyperthyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evening Primrose Oil Should NOT Be Used for Cervical Ripening in Any Pregnant Woman, Including Those with Hyperthyroidism History

Evening primrose oil (EPO) vaginal suppositories are not recommended for cervical ripening during labor induction, regardless of thyroid history, as the evidence shows no benefit and potential harm. The specific concern about hyperthyroidism is a red herring—EPO should be avoided in pregnancy altogether based on current evidence.

Why EPO Should Be Avoided in Pregnancy

The evidence against EPO use during pregnancy is clear:

  • A 1999 retrospective study found that oral EPO from 37 weeks until birth was associated with increased rates of prolonged rupture of membranes, oxytocin augmentation, arrest of descent, and vacuum extraction 1. This directly contradicts the intended purpose of cervical ripening.

  • A comprehensive 2009 review in American Family Physician explicitly states: "The use of evening primrose oil during pregnancy is not supported in the literature and should be avoided" 2.

While a 2024 Iranian trial 3 showed improved Bishop scores with vaginal EPO, this single positive study cannot override the established recommendation against its use, particularly given the 1999 study's findings of increased complications.

The Hyperthyroidism Question

There is no specific contraindication linking EPO to hyperthyroidism in the provided evidence. The Endocrine Society guidelines 4 extensively discuss management of hyperthyroidism in pregnancy but make no mention of EPO interactions or concerns. The key thyroid-related pregnancy risks include:

  • Inadequately treated maternal thyrotoxicosis increases risk of preterm delivery, intrauterine growth restriction, pre-eclampsia, and fetal death
  • Fetal hyperthyroidism can occur with transplacental passage of TSH receptor antibodies
  • Antithyroid drugs (PTU, MMI) are the mainstays of treatment

However, the absence of a specific EPO-thyroid contraindication is irrelevant because EPO should not be used for cervical ripening in ANY pregnant woman.

Clinical Algorithm for Cervical Ripening

For a parturient with history of hyperthyroidism requiring cervical ripening:

  1. Ensure thyroid function is adequately controlled before labor induction
  2. Use evidence-based cervical ripening agents as recommended in the ARRIVE trial 5:
    • Mechanical methods (Foley catheter)
    • Prostaglandin agents (misoprostol, dinoprostone)
    • These are the standard approaches with established safety profiles
  3. Avoid EPO entirely—it offers no proven benefit and carries potential risks

Common Pitfall

The major pitfall is assuming that "natural" or herbal remedies like EPO are safer alternatives to pharmaceutical agents. The evidence demonstrates the opposite: EPO lacks efficacy and may increase complications, while standard cervical ripening agents have well-established safety and efficacy profiles in pregnancy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.